Showing results (1-10 of 17) with videos related to
Sort By:
Pageof 2
International Journal of Molecular Sciences|August 6, 2020
P38α MAPK Signaling-A Robust Therapeutic Target for Rab5-Mediated Neurodegenerative DiseaseUrsula A Germann, John J AlamJournal of Alzheimer'S Disease : JAD|September 25, 2015
Selective Brain-Targeted Antagonism of p38 MAPKα Reduces Hippocampal IL-1β Levels and Improves Morris Water Maze Performance in Aged RatsJohn J AlamBiochemical Pharmacology|February 6, 2004
Regulation of inosine monophosphate dehydrogenase type I and type II isoforms in human lymphocytesJugnu Jain, Susan J Almquist, Pamella J Ford, et al.Proceedings of the National Academy of Sciences of the United States of America|October 21, 2003
Extracellular signal-regulated kinase 2 is necessary for mesoderm differentiationYao Yao, Wei Li, Junwei Wu, et al.Plos One|December 4, 2020
Continuous administration of a p38α inhibitor during the subacute phase after transient ischemia-induced stroke in the rat promotes dose-dependent functional recovery accompanied by increase in brain BDNF protein levelJohn J Alam, Michael Krakovsky, Ursula Germann, et al.The Journal of Pharmacology and Experimental Therapeutics|February 10, 2007
(S)-1-((S)-2-{[1-(4-amino-3-chloro-phenyl)-methanoyl]-amino}-3,3-dimethyl-butanoyl)-pyrrolidine-2-carboxylic acid ((2R,3S)-2-ethoxy-5-oxo-tetrahydro-furan-3-yl)-amide (VX-765), an orally available selective interleukin (IL)-converting enzyme/caspase-1 inhibitor, exhibits potent anti-inflammatory activities by inhibiting the release of IL-1beta and IL-18Woods Wannamaker, Robert Davies, Mark Namchuk, et al.Nature Communications|September 21, 2022
Preclinical and randomized clinical evaluation of the p38α kinase inhibitor neflamapimod for basal forebrain cholinergic degenerationYing Jiang, John J Alam, Stephen N Gomperts, et al.Alzheimer'S Research & Therapy|May 28, 2021
A phase 2 double-blind placebo-controlled 24-week treatment clinical study of the p38 alpha kinase inhibitor neflamapimod in mild Alzheimer's diseaseNiels D Prins, John E Harrison, Hui-May Chu, et al.Neurology|September 1, 2023
Association of Plasma Phosphorylated Tau With the Response to Neflamapimod Treatment in Patients With Dementia With Lewy BodiesJohn J Alam, Paul Maruff, Susan R Doctrow, et al.Pageof 2